IO Biotech Files Routine 8-K, Confirms Nasdaq Listing

Ticker: IOBT · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1865494

Io Biotech, Inc. 8-K Filing Summary
FieldDetail
CompanyIo Biotech, Inc. (IOBT)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, administrative, corporate-governance

TL;DR

**IOBT filed a standard 8-K, no new news to trade on.**

AI Summary

IO Biotech, Inc. filed an 8-K on January 8, 2024, primarily to disclose general information and confirm its status as a registrant with common stock (IOBT) listed on The Nasdaq Stock Market LLC. This filing, under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits), doesn't contain new material financial or operational news. For investors, this means there's no immediate new information to impact their investment decision, as it's a routine administrative filing confirming existing public information.

Why It Matters

This filing is largely administrative, confirming IO Biotech's existing status and Nasdaq listing, and does not contain new material information that would immediately impact stock valuation.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not introduce new financial or operational risks.

Analyst Insight

A smart investor would recognize this as a routine administrative filing with no new material information, thus requiring no immediate action or change in investment thesis for IO Biotech, Inc. (IOBT).

Key Numbers

  • $0.001 — Par value per share (The stated par value of IO Biotech, Inc.'s common stock.)

Key Players & Entities

  • IO Biotech, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Stock Market LLC (company) — the exchange where IO Biotech's common stock is registered
  • IOBT (company) — the trading symbol for IO Biotech's common stock
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • $0.001 (dollar_amount) — par value per share of common stock

FAQ

What is the purpose of this 8-K filing by IO Biotech, Inc.?

This 8-K filing by IO Biotech, Inc. on January 8, 2024, serves as a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily disclosing information under Regulation FD (Item 7.01) and Financial Statements and Exhibits (Item 9.01). It confirms the company's status and its common stock's registration on The Nasdaq Stock Market LLC.

What is the trading symbol for IO Biotech, Inc.'s common stock?

The trading symbol for IO Biotech, Inc.'s common stock is IOBT, as stated in the filing under 'Title of each class' and 'Trading Symbol(s)'.

On which exchange is IO Biotech, Inc.'s common stock registered?

IO Biotech, Inc.'s common stock is registered on The Nasdaq Stock Market LLC, as indicated in the filing under 'Name of each exchange on which registered'.

What is the par value per share of IO Biotech, Inc.'s common stock?

The par value per share of IO Biotech, Inc.'s common stock is $0.001, as specified in the filing under 'Common Stock, par value $0.001 per share'.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing was January 8, 2024, as stated at the beginning of the report.

Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-01-08 08:11:55

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar

Filing Documents

01

Item 7.01. Regulation FD Disclosure. Beginning on January 8, 2024, IO Biotech, Inc., a Delaware corporation (the "Company") will participate in the 42nd Annual J.P. Morgan Healthcare Conference (the "Conference"). The Company has updated the corporate presentation that it intends to use at the Conference and in meetings with investors, a copy of which was posted to the Company's website on January 8, 2024 (the "Investor Deck"). The Investor Deck includes, among other things, confirmation of its projected cash runway through the fourth quarter of 2025. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 IO Biotech, Inc., Investor Deck, dated as of January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IO BIOTECH, INC. Date: January 8, 2024 By: /s/ Mai-Britt Zocca, Ph.D. Name: Mai-Britt Zocca, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.